Drug intelligence / Profile preview

Na-APR-1 (M74) + Alhydrogel

Development stage
Phase 1
Lead developer
Sabin Vaccine Institute
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular
01

Overview

Na-APR-1 (M74) + Alhydrogel is a recombinant protein subunit vaccine candidate developed for the prevention of human hookworm infection. The vaccine consists of a catalytically inactive mutant of Necator americanus aspartic protease 1, known as Na-APR-1 (M74), which is adsorbed onto aluminum hydroxide gel adjuvant (Alhydrogel). The M74 mutation inactivates the enzyme to avoid potential toxicity while retaining immunogenicity. Upon administration, the vaccine induces neutralizing antibodies that target and block the enzymatic activity of native APR‑1 in hookworms, impairing their ability to digest host hemoglobin and feed on blood. This mechanism aims to reduce parasite burden and associated morbidity in infected individuals. Clinical trials have demonstrated that this formulation is safe, well-tolerated, and elicits robust antigen-specific IgG responses in healthy adults[3][5][2].

Other names
Necator americanus aspartic protease 1 (M74) + AlhydrogelRecombinant Na-APR-1(M74) with aluminum hydroxide adjuvant
02

Targets

Na-APR-1 (Necator americanus aspartic protease 1)

Beyond the preview

Go deeper on Na-APR-1 (M74) + Alhydrogel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Na-APR-1 (M74) + Alhydrogel.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call